Authors
Loading...
Analysis reveals EGLN1 as a potential biomarker for colorectal cancer, influencing patient survival and immune landscape.
Chen et al. (2025) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: